Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis
Akira Hirose, Masafumi Ono, Toshiji Saibara, Yasuko Nozaki, Kosei Masuda, Akemi Yoshioka, Masaya Takahashi, Naoaki Akisawa, Shinji Iwasaki, Jude A. Oben, Saburo Onishi – 29 May 2007 – Nonalcoholic steatohepatitis (NASH) is now the most frequent cause of chronic liver impairment in developed countries and is a suggested causative factor in the development of cryptogenic cirrhosis and hepatocellular carcinoma. At present there is no effective and accepted therapy for NASH.